MHRA to ask UK firms for data on API suppliers as new EU import rules draw nearer
This article was originally published in SRA
Executive Summary
The UK regulatory agency, the MHRA, is planning to ask drug marketing authorisation holders for information about the active pharmaceutical ingredients (APIs) they import into the UK for manufacture into non-centrally authorised drugs, with a view to minimising the risk of product shortages when new EU rules on API imports come into effect next year1.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.